Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial

BMC Psychiatry

Research Article

Hugo A Jørgensen¹  Eirik Kjelby²  Rune A Kroken²  Erik Johnsen³  Else-Marie Løberg⁴ 

[1] Department of Clinical Medicine, Psychiatry, University of Bergen, Norway;Division of Psychiatry, Haukeland University Hospital, Sandviken, Norway;Division of Psychiatry, Haukeland University Hospital, Sandviken, Norway;Department of Clinical Medicine, Psychiatry, University of Bergen, Norway;Division of Psychiatry, Haukeland University Hospital, Sandviken, Norway;University of Bergen, Inst. Biological and Medical Psychology, Norway;

关键词: Depressive Symptom;    Risperidone;    Olanzapine;    Quetiapine;    Antipsychotic Drug;   

DOI  :  10.1186/1471-244X-11-145

 received in 2011-02-18, accepted in 2011-08-31,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundEfficacy studies indicate anti-depressive effects of at least some second generation antipsychotics (SGAs). The Bergen Psychosis Project (BPP) is a 24-month, pragmatic, industry-independent, randomized, head-to-head comparison of olanzapine, quetiapine, risperidone and ziprasidone in patients acutely admitted with psychosis. The aim of the study is to investigate whether differential anti-depressive effectiveness exists among SGAs in a clinically relevant sample of patients acutely admitted with psychosis.MethodsAdult patients acutely admitted to an emergency ward for psychosis were randomized to olanzapine, quetiapine, risperidone or ziprasidone and followed for up to 2 years. Participants were assessed repeatedly using the Positive and Negative Syndrome Scale - Depression factor (PANSS-D) and the Calgary Depression Scale for Schizophrenia (CDSS).ResultsA total of 226 patients were included. A significant time-effect showing a steady decline in depressive symptoms in all medication groups was demonstrated. There were no substantial differences among the SGAs in reducing the PANSS-D score or the CDSS sum score. Separate analyses of groups with CDSS sum scores > 6 or ≤6, respectively, reflecting degree of depressive morbidity, revealed essentially identical results to the primary analyses. There was a high correlation between the PANSS-D and the CDSS sum score (r = 0.77; p < 0.01).ConclusionsThere was no substantial difference in anti-depressive effectiveness among olanzapine, quetiapine, risperidone or ziprasidone in this clinically relevant sample of patients acutely admitted to hospital for symptoms of psychosis. Based on our findings we can make no recommendations concerning choice of any particular SGA for targeting symptoms of depression in a patient acutely admitted with psychosis.Trial RegistrationClinicalTrials.gov ID; URL: http://www.clinicaltrials.gov/: NCT00932529

【 授权许可】

CC BY   
© Kjelby et al; licensee BioMed Central Ltd. 2011